Amgen Inc

24 iun. 2026, 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 iun. 2026, 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 iun. 2026, 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 iun. 2026, 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 iun. 2026, 19:53 UTC

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 iun. 2026, 19:22 UTC

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 iun. 2026, 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 iun. 2026, 19:51 UTC

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 iun. 2026, 23:06 UTC

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 iun. 2026, 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 iun. 2026, 19:56 UTC

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 iun. 2026, 20:06 UTC

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 iun. 2026, 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4 iun. 2026, 23:51 UTC

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3 iun. 2026, 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2 iun. 2026, 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1 iun. 2026, 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29 mai 2026, 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28 mai 2026, 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

27 mai 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, influenced by broader market dynamics, including declining US Treasury yields and inflation concerns.

26 mai 2026, 19:56 UTC

Amgen Inc. shares are lower as rising bond yields reflect inflationary pressures. Analysts maintain a positive outlook on the company's drug pipeline and capital allocation.

22 mai 2026, 20:06 UTC

Amgen Inc. is trading higher amid scrutiny of its rare disease therapy, Tavneos, linked to patient deaths and regulatory restrictions on new prescriptions.

21 mai 2026, 19:13 UTC

Amgen Inc shares rose after Japan allowed new prescriptions for a rare-disease drug, reversing a previous recommendation linked to reported deaths.

20 mai 2026, 19:51 UTC

Amgen Inc. shares are higher following the appointment of Thomas Dittrich as CFO and strong revenue growth of 12.3% over the past two years.

19 mai 2026, 20:03 UTC

Amgen Inc. shares are trading higher as analysts express optimism about revenue growth through 2027, despite a price target reduction to $427.

18 mai 2026, 19:52 UTC

Amgen Inc shares are lower as safety concerns over Tavneos intensify. Kissei Pharmaceutical advised caution after reports of 20 deaths linked to the drug.

15 mai 2026, 23:26 UTC

Amgen Inc shares are higher in after-market trading, despite social media concerns over recent decisions and a warning from Kissei Pharmaceutical regarding a rare drug.

14 mai 2026, 19:16 UTC

Amgen shares are lower as Piper Sandler cuts price target to $427 from $432. The stock is trading within its one-month range.

13 mai 2026, 23:02 UTC

Amgen Inc. shares are trading lower in after-market hours, following unusual activity earlier in the session and remaining below the 20-day moving average.